lectin from potato tuber
- Known as:
- lectin potato tuber
- Catalog number:
- L0139
- Product Quantity:
- 10 mg
- Category:
- -
- Supplier:
- BIO-VAR
- Gene target:
- lectin from potato tuber
Related genes to: lectin from potato tuber
- Gene:
- TSC2 NIH gene
- Name:
- TSC complex subunit 2
- Previous symbol:
- TSC4
- Synonyms:
- tuberin, LAM, PPP1R160
- Chromosome:
- 16p13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1989-05-25
- Date modifiied:
- 2019-04-23
Related products to: lectin from potato tuber
180 kDa secretory phospholipase A2 receptor,CLEC13C,C-type lectin domain family 13 member C,Homo sapiens,Human,M-type receptor,PLA2R,PLA2-R,PLA2R1,Secretory phospholipase A2 receptor200X FITC Lectin & Diluent200X FITC Lectin & Diluent200X FITC Lectin & Diluent200X FITC Lectin & Diluent200X FITC Lectin & Diluent CultrexAbrus preacatorius Gel _APA_ Immobilized Lectin, 2mLAbrus preacatorius Gel _APA_ Immobilized Lectin, 2mL, pre_packed in column with separate elution buffers and instruction booklet.Acid Phosphatase (ACP), Non-Prostatic Potato, >< per u>200 U per mg proteinAcid Phosphatase (ACP), Non-Prostatic Potato, >< per u>200 U per mg proteinAcid Phosphatase (ACP), Non-Prostatic Potato, >< per u>200 U per mg proteinAcid Phosphatase (ACP), Non-Prostatic Potato, >< per u>200 U per mg proteinACID PHOSPHATASE (ACP), Non-Prostatic Potato, >200 U_mg protein LiquidACID PHOSPHATASE (ACP), Non-Prostatic Potato, >200 U_mg protein LiquidACID PHOSPHATASE (ACP), Non-Prostatic Potato, >200 U_mg protein Liquid Related articles to: lectin from potato tuber
- - Source: PubMed
Publication date: 2026/04/16
Orbay MeltemSerin Hepsen MineKanmaz SedaSimsek ErdemIsik EsraAtik TahirCogulu OzgurOzkinay FerdaYilmaz SanemTekgul Hasan - To determine the frequency of pathogenic gene or copy number variants associated with epilepsy or neurodevelopmental disorders in individuals with tuberous sclerosis complex (TSC). - Source: PubMed
Publication date: 2026/04/15
Farach Laura SLeu CostinLal DennisSmith Althea RMontanucci LudovicaRichard Melissa AAu Kit SingNorthrup Hope - To identify the features of brain involvement and to characterize the genetic causes of tuberous sclerosis (TS) in patients in the Republic of Bashkortostan. - Source: PubMed
Mustafin R N - Perivascular epithelioid cell tumors (PEComas) are rare mesenchymal neoplasms characterized by melanocytic and smooth muscle differentiation. Although the kidney is a relatively common site, malignant renal PEComa is exceedingly rare, particularly in patients with tuberous sclerosis complex (TSC). Overlapping radiologic features between angiomyolipoma and malignant PEComa often result in diagnostic challenges. - Source: PubMed
Publication date: 2026/03/30
Li ShilongZhang NengYin Yongjin - The limited and inconsistent efficacy of existing therapies for tuberous sclerosis complex (TSC) has driven the exploration of novel strategies, including epigenetic regulation. GSK-J4, an inducer of global H3K27me3 accumulation, shows broad anti-tumor activity. However, its therapeutic potential in TSC remains unclear. In the study, we reported that GSK-J4 inhibited cell cycle progression and induced apoptosis in primary and MEFs. Mechanistically, or deletion reduced global H3K27me3, correlating with increased viability, accelerated cell cycle, and suppressed apoptosis-phenotypes reversed by GSK-J4. Moreover, GSK-J4 triggered endoplasmic reticulum stress (ERS) by activating the PERK-ATF4-CHOP axis, which concurrently downregulated the proto-oncogene c-Myc, outlining a GSK-J4→p-PERK→c-Myc inhibitory pathway. Notably, GSK-J4 synergized with rapamycin to enhance cell cycle arrest and apoptosis. , this combination alleviated renal impairment in - or -deficient models, suggesting a promising therapeutic strategy for TSC patients with suboptimal response to mammalian target of rapamycin complex 1 (mTORC1) inhibitors. Our study elucidates a specific ERS-dependent anti-tumor mechanism of GSK-J4 in -deficient contexts and demonstrates the synergistic efficacy of combining epigenetic and mTORC1 inhibitors. - Source: PubMed
Publication date: 2026/03/27
Lei XinLang TaoLi PingWu Changxin